CM
TVRD

Caption Management’s Tvardi Therapeutics TVRD Stock Holding History

Caption Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,164
Closed -$383K – 1909
2022
Q2 		$383K Buy
+1,164
New +$408K 0.01% 1134
2021
Q3 		– Sell
-197
Closed -$98.8K – 1852
2021
Q2 		$101K Sell
197
-2,453
-93% -$1.55M ﹤0.01% 1218
2021
Q1 		$2.07M Buy
+2,650
New +$1.81M 0.04% 504
2020
Q2 		– Sell
-1,928
Closed -$916K – 1219
2020
Q1 		$916K Buy
1,928
+361
+23% +$196K 0.05% 422
2019
Q4 		$909K Buy
+1,567
New +$1.1M 0.03% 524
2019
Q2 		– Sell
-1,563
Closed -$1.1M – 858
2019
Q1 		$1.1M Buy
+1,563
New +$936K 0.06% 339

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Caption Management's TVRD Position: Q3 2022 in Review

Caption Management sold out of Tvardi Therapeutics (TVRD) in Q3 2022, closing a stake of 1,164 shares — an estimated $383K sold.

Caption Management first reported a position in TVRD in Q1 2019 and held it in 6 quarters. The position peaked at $2.07M in Q1 2021. 164 funds tracked by Wall St. Rank hold TVRD as of Q3 2022.

  • Caption Management reported no remaining Tvardi Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Caption Management sold 1,164 Tvardi Therapeutics shares in Q3 2022, an estimated $383K.
  • Caption Management first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 6 quarters.
  • Caption Management's Tvardi Therapeutics position peaked at $2.07M in Q1 2021.
  • 164 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.